Free Newsletter
Pfizer's Nigerian deal held up by logistics
Last week's rumored settlement of the long-running Nigerian litigation against Pfizer lacks only a few final details, according to local and international media. U.K. newspapers have put the settlement amount at $75 million. Reportedly holding up the deal is some disagreement over just how that money will be allocated.
African news sources, however, are saying that local officials have announced the final terms, and the disagreement lies in the local governments' use of Pfizer's settlement dollars. Under the deal, $10 million goes to legal fees, $30 million to Kano State government, and $35 million to the victims. The $30 million is supposed to be earmarked for rebuilding a hospital and other healthcare initiatives.
As you know, Pfizer has been locked in lawsuits over a 1996 trial of the antibiotic Trovan. Pfizer came into Nigeria during a meningitis epidemic and tested the experimental drug; during the trial, 11 children died and some 200 others suffered deformities. The victims, victims' families, and local government have accused Pfizer of causing those injuries and conducting the trial improperly. The company maintains that the deaths and injuries stemmed from the meningitis itself, not the treatment.
Now, 13 years later, Pfizer is calling on the government and courts to make the settlement disbursement a "transparent" process to ensure that the money gets to the victims and the government funds are used for specific healthcare projects.
- read the All Africa story
- see the Wall Street Journal article
Related Articles:
Has Pfizer settled the Trovan case?
Courts resurrect suits against Pfizer
Pfizer aims for settlement on Trovan
Forbes digs into 'Pfizer's Nigerian nightmare'
Letters show Nigeria OK'd Pfizer trial
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession





